Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1987 1
2002 1
2004 2
2005 2
2006 2
2007 3
2008 2
2009 7
2010 2
2011 2
2012 2
2013 2
2014 4
2015 4
2016 2
2017 4
2018 9
2019 9
2020 6
2021 6
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Gastric Adenocarcinoma"
Page 1
The heterogeneity of cancer-associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment.
Yamamoto Y, Kasashima H, Fukui Y, Tsujio G, Yashiro M, Maeda K. Yamamoto Y, et al. Cancer Sci. 2023 Jan;114(1):16-24. doi: 10.1111/cas.15609. Epub 2022 Oct 19. Cancer Sci. 2023. PMID: 36197901 Free PMC article. Review.
The prognosis for patients with cancers known for a highly activated stromal reaction, including diffuse-type (scirrhous) gastric cancer, consensus molecular subtype 4 (CMS4) colorectal cancer, and pancreatic ductal adenocarcinoma, is extremely poor. To explo …
The prognosis for patients with cancers known for a highly activated stromal reaction, including diffuse-type (scirrhous) gastric …
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, and current guidelines do not recommend any specific treatments for these pa …
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more …
Advances in the treatment of gastric cancer.
Ilson DH. Ilson DH. Curr Opin Gastroenterol. 2018 Nov;34(6):465-468. doi: 10.1097/MOG.0000000000000475. Curr Opin Gastroenterol. 2018. PMID: 30303856 Review.
Trifluridine/tipiracil treatment in chemotherapy-refractory gastric cancer improved survival compared to placebo and will emerge as a late-line therapy option. Phase II and III trials indicate activity for the immune checkpoint inhibitors pembrolizumab and nivolumab …
Trifluridine/tipiracil treatment in chemotherapy-refractory gastric cancer improved survival compared to placebo and will emer …
Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS. Jothimani D, et al. Med Clin North Am. 2023 May;107(3):491-504. doi: 10.1016/j.mcna.2023.01.002. Epub 2023 Feb 20. Med Clin North Am. 2023. PMID: 37001949 Review.
Clinically significant portal hypertension (CSPH) is an important prognostic milestone in patients with liver cirrhosis. This is a pre-symptomatic phase that predicts the development of varices, ascites and importantly increased risk of Hepatocellular carcinoma (HCC …
Clinically significant portal hypertension (CSPH) is an important prognostic milestone in patients with liver cirrhosis. This is a pr …
Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.
Fichtl A, Seufferlein T, Zizer E. Fichtl A, et al. BMC Gastroenterol. 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0. BMC Gastroenterol. 2023. PMID: 37986043 Free PMC article. Review.
Its high efficacy and safety in the management of treatment-refractory ascites and variceal bleeding have been extensively proven. ...Coexisting portal hypertension in HCC often results in limited treatment options and a poor prognosis. Previous studies have shown t …
Its high efficacy and safety in the management of treatment-refractory ascites and variceal bleeding have been extensively proven. .. …
Current status and future perspectives in HER2 positive advanced gastric cancer.
Roviello G, Catalano M, Iannone LF, Marano L, Brugia M, Rossi G, Aprile G, Antonuzzo L. Roviello G, et al. Clin Transl Oncol. 2022 Jun;24(6):981-996. doi: 10.1007/s12094-021-02760-0. Epub 2022 Jan 29. Clin Transl Oncol. 2022. PMID: 35091998 Review.
Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in unresectable or metastatic disease. ...In this review, we summarize the available data on the mechanisms underlying primary and secondary resistance toHER2-targeted th …
Gastric cancer is one of the most common malignancy worldwide with a prognosis less than 1 year in unresectable or metastatic …
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL. Weinberg BA, et al. Oncologist. 2018 Oct;23(10):1171-1177. doi: 10.1634/theoncologist.2018-0034. Epub 2018 Apr 27. Oncologist. 2018. PMID: 29703766 Free PMC article.
PURPOSE: The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transformed by the U.S. ...IMPLICATIONS FOR PRACTICE: Pembrolizumab is approved by the U.S. Food and Drug Administration for patients with refr …
PURPOSE: The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transf …
The portal hypertension syndrome: etiology, classification, relevance, and animal models.
Bosch J, Iwakiri Y. Bosch J, et al. Hepatol Int. 2018 Feb;12(Suppl 1):1-10. doi: 10.1007/s12072-017-9827-9. Epub 2017 Oct 24. Hepatol Int. 2018. PMID: 29064029 Review.
Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension. ...TIPS might b …
Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asy …
DNMT3A overexpression is associated with aggressive behavior and enteroblastic differentiation of gastric adenocarcinoma.
Kataoka I, Funata S, Nagahama K, Isogaya K, Takeuchi H, Abe N, Shibahara J. Kataoka I, et al. Ann Diagn Pathol. 2020 Feb;44:151456. doi: 10.1016/j.anndiagpath.2019.151456. Epub 2019 Dec 14. Ann Diagn Pathol. 2020. PMID: 31862523
Gastric adenocarcinoma (GA) with enteroblastic differentiation is a subset of gastric cancer with poor prognosis. ...Our findings suggest DNMT3A as a potential therapeutic target for this conventional therapy-refractory cancer subtype....
Gastric adenocarcinoma (GA) with enteroblastic differentiation is a subset of gastric cancer with poor prognosis …
PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.
Xu H, Hong Z, Xu M, Kong Y, Ma Y, Shan C, Xing P, Zhang L. Xu H, et al. Front Immunol. 2022 Jul 7;13:926740. doi: 10.3389/fimmu.2022.926740. eCollection 2022. Front Immunol. 2022. PMID: 35874658 Free PMC article.
Patients with metastatic gastric cancer had limited treatments and often had a somber prognosis, especially when patients were unable to tolerate high-intensity cytotoxic treatment due to poor physical condition or organ dysfunction after the failure of standard the …
Patients with metastatic gastric cancer had limited treatments and often had a somber prognosis, especially when patients were …
71 results